Medscape2 天
Senolytics: Zombie Cells, Longevity, and What’s Possible
With clinical trials results trickling in, “antiaging” drugs that clear away senescent cells are proving to be promising — ...
The Manila Times3 天
Microbix & ACPCC support efforts to eliminate cervical cancer in the Indo-Pacific
EPICC HPV Elimination Partnership being supplied PROCEEDxFLOQ QAPs to Support Test Accuracy MISSISSAUGA, Ontario and ...
American Association of Individual Investors3 天
Why Monopar Therapeutics Inc.’s (MNPR) Stock Is Up 15.06%
Monopar Therapeutics Inc.’s MNPR share price has surged by 15.06%, which has investors questioning if this is right time to sell.
生物通1 天
综述：胸膜感染及其他胸膜机化形式的胸腔内纤溶疗法：现状与展望
在一项针对单链尿激酶型纤溶酶原激活剂（single chain urokinase plasminogen activator，scuPA）的研究中，研究者测量了接受不同剂量 scuPA 治疗患者胸腔积液中的相关指标，以评估不同剂量方案的效果及其与临床结果的关系。scuPA 对胸腔积液中主要的 PA 抑制剂 —— 纤溶 ...
生物通3 天
可溶性尿激酶型纤溶酶原激活剂受体（SuPAR）对髋部骨折手术高危 ...
可溶性尿激酶型纤溶酶原激活剂受体（Soluble urokinase plasminogen activator receptor，SuPAR）是一种炎症和免疫激活的生物标志物，已被证实与老年人多种疾病的死亡率相关。其在非心脏手术术前评估中的预后价值颇具前景。然而，截至目前，尚无针对接受髋部骨折手术 ...